AI Cancer Risk Assessment Tool Has Been Launched
A new online assessment helps individuals identify potential cancer risk factors to discuss with their physician.
Updated on Oct. 6, 2026 in Cancer
Live Poll
Do you trust AI-based tools to accurately assess your personal health risk factors?
YD Bio and EG BioMed have released an AI-powered survey designed to evaluate personal risk for ten different cancer types. The service is currently available to users in the United States, Canada, and Taiwan.
Why it matters
The tool aims to help users identify their health risk factors based on lifestyle and medical history. It is intended to facilitate more informed conversations during appointments with healthcare providers.
The tool uses a 48-feature pan-cancer model and ten cancer-specific models derived from over 140 research studies. This assessment is not a clinical diagnostic device or a formal cancer screening.
The players
YD Bio
A biotechnology firm involved in developing diagnostic tools and AI-driven health assessments.
EG BioMed
A medical technology company based in Taipei, Taiwan, specializing in cancer risk evaluation software.
The details
Users complete a 52-question survey covering health history, diet, and lifestyle, which takes approximately 10 minutes. An AI-driven system processes this information alongside a rule layer to generate a personalized risk report. The platform does not involve clinical procedures such as blood draws, imaging, or physical exams.
Timeline
January 2026: YD Bio and EG BioMed signed a merger agreement.
March 2026: The companies launched a nationwide telehealth platform.
October 6, 2026: Launch of the AI Cancer Risk Assessment tool.
2026: Anticipated closing of the YD Bio and EG BioMed merger.
Health Landscape
This tool arrives as part of a broader trend of integrating AI into personalized health assessments to supplement standard clinical protocols. It sits outside the established oncology standard of care, which relies on physical screening, imaging, and diagnostic testing.
Users can utilize this $10 promotional assessment to organize their personal health information before a wellness checkup. It is important to remember this is not a diagnostic test and any concerns about cancer risk should be addressed directly with a physician.
The takeaway
This tool provides a structured way to summarize lifestyle factors that may impact cancer risk. Use the resulting report as a starting point for a conversation with your primary care doctor about necessary screenings or preventive habits.
What happens next
The merger between YD Bio and EG BioMed is expected to close by the end of 2026.
Further reading
For more on evaluating diagnostic developments, visit the Cancer section.
More information
To review the survey details or access the platform, visit the AI Cancer Risk Assessment website.
Live Poll
Do you trust AI-based tools to accurately assess your personal health risk factors?
